Intest CorpINTT

InTest Corp’s latest quarter is a masterclass in talking up non-semiconductor tailwinds while quietly haemorrhaging operating cash. The company lifted its 2026 revenue guidance to $130m-$135m after what it calls a “good start” to the year, but the cash machine delivered $789,000 in net income on $12.4m of diluted shares-six cents per share-while operating activities drained $3.3m. The press release chirps about “strong execution” and 69% of revenue from non-semiconductor end markets, which is corporate-speak for “we’re not concentrated to the chip cycle right now,” but it doesn’t explain why cash flow is still in reverse.

What InTest actually sells are test and process technology solutions for manufacturing and testing across semiconductor, auto/EV, defence/aerospace, industrial, life sciences, and safety/security. That’s a broad toolkit, yet the $30.5m inventory line-down just $621,000 in the quarter-suggests the company is still holding rather more stock than the average lean-manufacturing advocate would cheer. Research and development spent $2.6m, a sensible line until you notice capex chewed up another $644,000, and the board’s recent change-of-control agreement with CEO Rich Rogoff quietly flags a 20% excise tax risk if the IRS deems his exit package an “excess parachute payment.”

The balance sheet still looks tidy: $150.8m in assets, $46.3m in liabilities, $104.5m in equity, and $12.9m in cash and equivalents. But between the $3.3m operating cash burn and the $30.5m inventory pile, the numbers whisper a different story to the sunny revenue guidance and end-market mix tout. Research and development expense totalled $2.6m for the quarter, while payments for property, plant and equipment clocked in at $644,000. Earnings per share, diluted, were $0.06 on 12.4m weighted average shares. Operating income was $954,000 against a net income of $789,000. Inventory, net, stood at $30.5m, with a quarterly decrease of $621,000. Net cash used in operating activities was $-3.3m. Cash and cash equivalents at carrying value were $12.9m. All figures are drawn from the 10-Q for the quarter ended 31 March 2026, filed with the SEC.

The company’s investor rail points to a widening addressable market across auto/EV, defence/aerospace, and life sciences, but the operating reality is that cash flow is still negative while the board keeps signing off on CEO parachute language that casually warns of a 20% excise tax if the golden-parachute rules kick in. That’s a tension worth watching ahead of any further incentive tweaks.

For readers hunting a chart route, the SEC’s Company Facts API and submissions index are the cleanest rails for fresh filings, while the EDGAR feed remains the canonical source for the latest 10-Q, 8-Ks, and insider forms. There are no analyst estimates or valuation commentary in the evidence, so any technical levels or trading commentary would be invention.

The next meaningful test is whether the raised revenue guidance translates into positive operating cash flow by year-end. Until then, the company is running on guidance and goodwill, while the balance sheet quietly reminds everyone that cash is still flowing out the door. If inventory begins to turn more quickly or capex slows, those would be the first green shoots worth noting.